brain cancer – pharmaceutical daily

April 24, 2020 Off

Noxxon kicks off brain cancer patients recruitment

Noxxon Pharma said Friday that recruitment of patients in second cohort has been initiated for the middle dose cohort for the Phase 1/2 NOX-A12 plus radiotherapy brain cancer trial.

January 16, 2018 Off

Midatech conducts study on childhood brain cancer drug in USA

By Dino Mustafić

Midatech Pharma will conduct a study of an investigational new drug for the treatment of the fatal childhood brain cancer…

October 2, 2015 Off

Merck and DNAtrix to evaluate the efficacy and safety of DNX-2401

By Dino Mustafić

Merck, known as MSD outside the United States and Canada, and DNAtrix announced on Thursday that they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.